Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institutes of Health (NIH) plans to issue a Notice of Funding Opportunity aimed at supporting the development, validation, and application of advanced three-dimensional (3-D) tissue models for drug efficacy testing. These innovative non-animal models are designed to replicate the structural, biochemical, and mechanical aspects of human tissues in order to improve the predictive accuracy of drug responses. The project focuses on creating adaptable 3-D models compatible with high-throughput screening platforms to accelerate drug discovery and development across various disease areas. This effort builds upon prior initiatives targeting 3-D skin and other tissue models, emphasizing the use of expertise and infrastructure from the NCATS 3-D Bioprinting Laboratory. Applicants are expected to design tissue models that balance complexity and simplicity to ensure physiological relevance while maintaining robustness and reliability for drug screening applications. The collaboration excludes clinical trials and is supported under the legal authority of the Cures Acceleration Network. The funding opportunity signifies an important step toward replacing animal testing with more predictive human-relevant models, enhancing the efficiency of therapeutics development. Interested parties can contact Dr. Dobrila D. Rudnicki at NIH for more information.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases.
The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.